22/03/2015 - 19:24 SAN FRANCISCO– Dupilumab met its safety endpoints and significantly outperformed placebo for adults with moderate to severe atopic dermatitis, accor... More » Visit websiteField of Interest: DermatologyCategories: FPN || NewsFPN || DermatologyIMN || NewsIMN || DermatologySAN || Clinical NewsSAN || NewsSAN || Atopic DermatitisAmerican Academy of DermatologyNews Feed: Internal Medicine News - Dermatology
